Funds managed by BlackRock added $40m to the $60m supplied for the drug development technology developer by investors including Novo, Evotec and Bristol Myers Squibb in May.
Author: Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Corporates help eGenesis generate $125m
Xenotransplantation technology developer eGenesis took its total funding to $263m in a series C round backed by Bayer and Fresenius Medical Care.
Artizan crafts $11m series A2 round
Biohaven Therapeutics co-led Artizan Biosciences’ latest round as part of an option and licensing agreement focusing on its inflammatory bowel disease drug candidates.
Tenaya Therapeutics takes in $106m
GV returned to help heart disease drug developer Tenaya boost its overall funding to approximately $248m.
Oxular eyes $37m round
Hovione Scientia and Consort Medical-backed Oxular has secured funding that will support phase 2 trials for a treatment for diabetic macular oedema.
Markforged devises reverse merger plan
Microsoft, Porsche and Siemens have all scored another win as Markforged pursues a reverse merger that will net it $425m in gross proceeds.
Berkshire Grey picks reverse merger route
SoftBank’s robotics portfolio company Berkshire Grey has lined up a reverse merger with Revolution Acceleration Acquisition Corp and will be valued at $2.7bn.
ReNew Power charges towards Nasdaq
Having abandoned plans for an IPO three years ago, ReNew Power has now settled on a reverse merger and will secure proceeds worth $1.2bn.
Xylowatt runs out of steam
John Cockerill and Air Liquide-backed Xylowatt has declared bankruptcy after failing to build a market for its biomass energy technology.
Corporate venturing deal net: 15-19 February 2021
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Xingsheng Youxuan pockets $2bn
Tencent has backed another round for the bulk grocery shopping service, which also attracted China Evergrande Group and valued Xingsheng at $6bn pre-money.
Humacyte hooks into Alpha Healthcare
Fresenius Medical Care and Access Industries-backed Humacyte will merge with Alpha Healthcare Acquisition Corp to become a public business with a market cap of $1.1bn.
CrowdStrike captures Humio for $400m
Dell is celebrating an exit as Humio agreed to a $400m acquisition by CrowdStrike, less than a year after Dell led a $20m series B round for the cybersecurity company.
Adjuvant stimulates $300m fund
Merck and Novartis joined a host of philanthropic and state-backed entities for a $300m fund that will invest in medical technologies for conditions often ignored by venture capital.